Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$123.57
▲ $1.55 (+1.3%)
Market data updated: 09/25 07:49 PM
Fundamentals updated: 09/24/2026
News analyzed: 09/25/2026
Market Cap
$12.19B
Day Range
$121.72 - $124.49
52-Week Range
$92.77 - $127.99
Beta
—
Next Earnings
27.10.2026
Support
$107.10
Resistance
$127.50
EHC is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-3.8% (1Y)
Strengths: 12/29 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 24.2%
Growth
Biggest negative driver
MACD
MACD histogram is negative — falling momentum
Technical
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
66
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
71
Quality
58
Value
50
Momentum
64
Risk
50
Sentiment
98
Fundamental
67
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Encompass Health Corporation highlights its strong financial performance and growth outlook. The company reported a 9.6% revenue increase and 10.7% rise in adjusted earnings per share in Q2, prompting upward revisions to full-year guidance. Analysts praise its operational strength, capacity expansion—including new facilities—and potential for 6-8% multi-year discharge growth. Stock valuations have been positively adjusted, with some analysts estimating the shares could be 19% undervalued, despite recent financing activities like a $100 million senior notes issuance. Overall, the focus remains on its robust growth narrative and leadership in the rehab hospital sector.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Encompass Health Corporation. News trend score: 98. Reason: 10 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
24
🎯 Conviction (vs. Emotion)
41
Psychology
27
Fundamentals
67
Technical
64
Valuation
50
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+20%
Market Narrative
64
Fundamental Reality
41
Narrative Gap
+23
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests detached euphoria (score 26) as EHC trades well above its 200-day average with uniformly positive news sentiment, despite neutral momentum and modest volume. The narrative gap (64 vs. 36) implies traders may be overestimating fundamentals or growth potential. Key open question: Will the stock’s relative outperformance (herding score 11) sustain, or will sentiment cool if momentum weakens further? The lack of panic or overconfidence signals suggests a cautious but optimistic stance, not extreme risk-taking.
Updated: 09/08/2026, 11:17 PM
What could change this?
👥 What the crowd believes
"Net operating revenue climbed 9.6% to $1.597 billion, and adjusted earnings per share rose 10.7% to $1.55"
"fair value estimates moving from about US$145.25 to roughly US$148.17"
"Encompass Health's capacity expansion, new facilities and North Carolina pipeline could fuel 6-8% multi-year discharge growth"
"Encompass Health stock has more than doubled over the past 5 years, yet current checks still suggest the shares trade at a discount"
📈 4D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Thorstein Veblen — 71/100
🔴 Weakest match
Benjamin Graham (Enterprising Investor) — 9/100
🗣️ Why do they disagree?
The stark divide in verdicts for EHC reflects a tension between cyclical optimism and fundamental caution. Samuel Armstrong Nelson’s high score suggests the stock may be near a cyclical low, while Peter Lynch and Thorstein Veblen see potential but question whether the price already embeds most of its growth. Meanwhile, the cluster of moderate scores from Smith, Housel, and Veblen indicates a cautious ‘holdable but not effortless’ stance, balancing growth signals with lingering concerns. At the other end, Benjamin Graham’s near-failure of defensive criteria and Walter Bagehot’s liquidity warnings contrast sharply with Nelson’s bullish cycle reading, illustrating how deep-value and liquidity-focused methodologies dismiss the stock entirely. Even Jack Schwager’s ‘no setup’ verdict and Howard Marks’ late-cycle caution imply a consensus that the stock’s risks outweigh its rewards—unless one prioritizes cyclical timing over fundamentals.
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 71
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 67
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 62
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 56
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 50
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 43
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 43
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 41
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 40
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 40
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 39
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 27
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 22
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 12
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 9
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Based on the last 283 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (6 bullish · 3 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
95.7%
Operating Margin
17.7%
Net Margin
9.5%
EBITDA Margin
—
ROE
23.2%
ROA
8.0%
ROIC
—
EPS
$5.62
Cash
$72.20M
Total Debt
—
Current Ratio
1.08
Debt/Equity
1.02
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 1.7.2026 | $0.190 |
| 30.6.2026 | $0.190 |
| 1.4.2026 | $0.190 |
| 31.3.2026 | $0.190 |
| 2.1.2026 | $0.190 |
| 1.1.2026 | $0.190 |
| 1.10.2025 | $0.190 |
| 30.9.2025 | $0.190 |
| 1.7.2025 | $0.170 |
| 30.6.2025 | $0.170 |
| 1.4.2025 | $0.170 |
| 31.3.2025 | $0.170 |
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$24.38
Tangible Book Value per Share (Tangible NAV)
$21.30
Sentiment based on basic keywords (not AI) — 10 positive, 8 neutral, 2 negative out of the last 20 articles.
Yahoo · 25.9.2026
Yahoo · 25.9.2026
MT Newswires · 24.9.2026
Yahoo · 24.9.2026
PR Newswire · 24.9.2026
Yahoo · 24.9.2026
Zacks · 24.9.2026
SeekingAlpha · 24.9.2026
StockStory · 17.9.2026
Yahoo · 17.9.2026
MT Newswires · 15.9.2026
PR Newswire · 15.9.2026
Yahoo · 15.9.2026
Benzinga · 15.9.2026
Zacks · 15.9.2026
Yahoo · 15.9.2026
Insider Monkey · 7.9.2026
Yahoo · 7.9.2026
Zacks · 4.9.2026
Yahoo · 4.9.2026
Encompass Health Corporation (EHC) currently has a StockIQ AI score of 66/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
EHC currently scores 66/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
EHC's technical score is 64/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 24.2%; Net income growth: 24.2%; Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: MACD histogram is negative — falling momentum; Price is below the SAR point — downtrend; CMF 20 days: -0.12.
Yes — EHC has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 10 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Darby John Patrick | Exercise of Derivative Securities | 31.8.2026 | 4,858 | +4,858 | $35.06 |
| Price Andrew L | Open Market Sale | 31.8.2026 | 5,211 | -5,211 | $120.93 |
| Darby John Patrick | Exercise of Derivative Securities | 31.8.2026 | 4,858 | -4,858 | — |
| Darby John Patrick | Open Market Sale | 31.8.2026 | 4,858 | -4,858 | $121.09 |
| Darby John Patrick | Open Market Sale | 10.8.2026 | 8,906 | -8,906 | $125.95 |
| Tarr Mark J | Open Market Sale | 10.8.2026 | 1,579 | -1,579 | $126.06 |
| Tarr Mark J | Open Market Sale | 10.8.2026 | 171,569 | -171,569 | $125.46 |
| COLTHARP DOUGLAS E | Open Market Sale | 10.8.2026 | 18,869 | -18,869 | $125.38 |
| COLTHARP DOUGLAS E | Open Market Sale | 10.8.2026 | 50,508 | -18,869 | $125.38 |
| Tarr Mark J | Open Market Sale | 10.8.2026 | 269,393 | -171,569 | $125.46 |
| Tarr Mark J | Open Market Sale | 10.8.2026 | 267,814 | -1,579 | $126.06 |
| Darby John Patrick | Open Market Sale | 10.8.2026 | 75,041 | -8,906 | $125.95 |
| Christie Edward M III | Grant/Award from Employer | 16.7.2026 | 248 | +248 | $112.43 |
| Reidy Christopher R | Grant/Award from Employer | 16.7.2026 | 319 | +319 | $112.40 |
| Reidy Christopher R | Grant/Award from Employer | 16.7.2026 | 17,777 | +319 | $112.40 |
| Christie Edward M III | Grant/Award from Employer | 16.7.2026 | 9,345 | +248 | $112.43 |
| Hayes Cain A | Grant/Award from Employer | 15.7.2026 | 4 | +4 | — |
| HERMAN JOAN E | Grant/Award from Employer | 15.7.2026 | 85 | +85 | — |
| KATZ LESLYE G | Grant/Award from Employer | 15.7.2026 | 85 | +85 | — |
| CARMICHAEL GREG D | Grant/Award from Employer | 15.7.2026 | 29 | +29 | — |
| O'Connor Kevin J. | Grant/Award from Employer | 15.7.2026 | 19 | +19 | — |
| SCHLICHTING NANCY M | Grant/Award from Employer | 15.7.2026 | 40 | +40 | — |
| Williams Terrance | Grant/Award from Employer | 15.7.2026 | 29 | +29 | — |
| Christie Edward M III | Grant/Award from Employer | 15.7.2026 | 11 | +11 | — |
| Reidy Christopher R | Grant/Award from Employer | 15.7.2026 | 21 | +21 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
3,000,467 shares short as of 2026-09-15 · vs. 3,240,604 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
53.9% of trading volume this week was short selling, vs. 69.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology